Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

GSK (GSK) has agreed to sell 500K doses of its avian flu vaccine to Canada to protect the country's at-risk individuals and ...

International biotechnology company GlaxoSmithKline is moving its vaccine and infectious disease research teams to Cambridge, ...

Multiple vaccine shots are needed to boost vasculitis patients’ immunity against COVID, especially if they have been treated ...

The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active ...

GlaxoSmithKline share price has surged more than 36% in two sessions after the announcement of Q3 results. The stock has ...

Dr. Juliet Addo, Academic Engagement Director for Ghana and Head of the Africa Open Lab at GSK, has reaffirmed the importance ...

Where could be the top place to invest this spring? Europe. That's according to the latest edition of the hugely influential ...

Shares of GlaxoSmithKline Pharmaceuticals Ltd ended at ₹2,608, up by ₹275.75, or 11.82%, on the BSE. Brokerage firms, ...

GSK Pharma had reported a consolidated net profit of Rs 230 crore for Q3 FY25. This marks a significant surge of nearly 400 ...

The company's total revenue also saw a rise. In the previous year's Q3 or Q3FY24, the total revenue attained by the company stood at Rs 805.26 crore. This rose to Rs 949.42 crore in the span of a year ...

A late-session recovery helped the 30-share BSE Sensex rise 57.65 points (0.08%) to close at 75,996.86. Earlier in the ...